2 results match your criteria: "DAPI-German Institute for Drug Use Evaluation[Affiliation]"
Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients.
Int J Cardiol
October 2016
DAPI-German Institute for Drug Use Evaluation, Unter den Linden 19-23, 10117 Berlin, Germany; Department of Pharmacology, Biocenter, Goethe-University Frankfurt, Max-von-Laue-Strasse 9, 60438 Frankfurt am Main, Germany.
Background: Suboptimal adherence to antihypertensives leads to adverse clinical outcomes. This study aims to determine and compare medication adherence and persistence to different first-line antihypertensive drug classes in a large cohort.
Methods: A cohort study was performed using claims data for prescriptions in the German statutory health insurance scheme that insures approximately 90% of the population.
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
Int J Clin Pharmacol Ther
January 2012
DAPI-German Institute for Drug Use Evaluation, Eschborn, Germany.
Objective: To compare the persistence (treatment duration) of basal insulin supported oral therapy (BOT) using insulin glargine (GLA) or NPH insulin (NPH) in Type-2 diabetic patients.
Methods: This retrospective cohort study reports results from an analysis of claims data from prescriptions for ambulatory patients within the German Statutory Health Insurance scheme. The study is based on claims data from more than 80% of German community pharmacies.